Tag Archives: in-licensing

Hot Investor Mandate 1: China-Based Family Office Seeks Global Investment and In-Licensing Opportunities with Focus in USA & UK

26 Apr

A venture capital fund/family office based in Hangzhou, China currently manages two venture funds in addition to a number of private capital accounts through which investments are made – these two funds focus on life sciences. The firm primarily makes equity investments in early-stage rounds ranging from $1 million initially; for later-stage to pre-IPO companies, the firm looks to make initial equity investments ranging from $3-5 million. The firm looks for companies located around the globe, with a preference in the US and Europe (UK). Currently, the firm is also actively seeking in-licensing opportunities in biotech innovations that has a China angle. The firm is actively looking for investment opportunities.

The firm is a flexible and opportunistic investor and will consider therapeutics, medical devices, and diagnostics. The firm is open to all kinds of sectors and indications. For therapeutics, the firm has specific focuses on novel candidates for disease, PD1-base approaches, gene therapy, oncology, cardiovascular diseases, and small molecules. For medical devices, the firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is also interested in diagnostics although this area is less of a focus. In terms of therapeutics, the firm will look at products of pre-clinical stage and later stages from phase II to phase III. Regarding medical devices, the firm will invest at any stage of development.

The firm is looking for private companies only. The firm typically has no specific requirements for the management team, but this depends on how much the firm invests. The firm looks to take a board seat following the investment and is comfortable acting as both a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Korean Pharmaceutical Company Seeks In-Licensing Opportunities at All Stages, with Strong Interest in NCEs and First-In-Class Drugs

26 Apr

A large pharmaceutical company headquartered in Seoul, South Korea specializes in developing, manufacturing, and supplying pharmaceutical products that contribute to the health and happiness of humankind, including resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and aging. The company’s strengths lie in the development of raw vitamins, probiotics, and antimicrobials, as well as strong market share in clinics and hospitals, and robust experience in marketing, promotion, distribution, and R&D.

The company works with global pharmaceutical companies to manufacture original prescription drugs and utilizes is internal synthesis capacity to manufacture a wide variety of generic prescription drugs. The company is currently expanding into functional health food, medical device, cosmetic, and beverage industries and evolving into a total healthcare company of global proportions. The company is actively seeking early to late-stage drugs globally for in-licensing, co-development, or acquisition.

The company is seeking early to late-stage therapeutic drugs with strong interests in these following indications: oncology, CNS, gastrointestinal (GI), autoimmune, endocrine and metabolic diseases. The company is most interested in NCEs and first/best-in-class MOA.

The company seeks to partner with teams with strong scientific expertise who are working on novel technologies, and is flexible in terms of distribution rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Subsidiary of Large USA and China-Based Biotech Seeks Investment and In-Licensing Opportunities in Cell & Gene Therapies, Invests Up to $10M

19 Apr

An emerging company with China headquarters is focusing on the development of the best-in-class immunotherapy technology for cancer cure. Teamed up with outstanding immunologists and molecular biologists, the firm has generated a strong pipeline of Chimeric Antigen Receptor (CAR) product candidates to treat a wide variety of liquid and solid tumors. The firm is a subsidiary company of another established public biotech company with offices in USA and China. The firm is actively seeking investment, partnering and licensing opportunities to expand the pipeline of therapeutics and offerings. Typical allocations are $1-10 M.

The firm’s sectors of focus are cell and gene therapies, cell engineering, processing and manufacturing technologies and tools.

The firm may seek a board seat depending upon size of investment. They are open to working with all stages of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

<span>%d</span> bloggers like this: